A 55-Year-Old Diabetic Woman with Feet Pain

  • Robert Fuino
  • Rup Tandan
  • Waqar WaheedEmail author


Diabetic polyneuropathy (DPN) is a result of nerve damage resulting in varying degrees of sensorimotor disturbances. It most commonly presents as a distal sensory polyneuropathy, although other presentations are possible. While pain is not always present in this condition, it occurs frequently enough to make it the primary reason patients seek care. Nerve damage resulting from impaired glycemic control is poorly understood but has a relationship with reactive oxygen species. The diagnosis is determined by the presence of neuropathic symptoms, examination findings, confirmation by electro-diagnostic testing, and, if required, skin biopsy. The mainstays of treatment include control of blood glucose, prevention of ulcers and occult foot injuries, and pain control.


Diabetic neuropathy Neuropathic pain Nerve conduction studies Polyneuropathy Foot pain and diabetes 


  1. 1.
    Callaghan BC, Little AA, Feldman EL, Hughes RA. Enhanced glucose control for preventing and treating diabetic neuropathy. Cochrane Database Syst Rev. 2012;6:CD007543.PubMedPubMedCentralGoogle Scholar
  2. 2.
    Vincent AM, Russell JW, Low P, Feldman EL. Oxidative stress in the pathogenesis of diabetic neuropathy. Endocri Rev. 2004;25(4):612–28.CrossRefGoogle Scholar
  3. 3.
    Vincent AM, Callaghan BC, Al S, Feldman EL. Diabetic neuropathy: cellular mechanisms as therapeutic targets. Nat Rev Neurol. 2011;7(10):573–83.CrossRefGoogle Scholar
  4. 4.
    Vincent AM, Perrone L, Sullivan KA, Backus C, Sastry AM, Lastoskie C, et al. Receptor for advanced glycation end products activation injures primary sensory neurons via oxidative stress. Endocrinology. 2007;148(2):548–58.CrossRefGoogle Scholar
  5. 5.
    Padilla A, Descorbeth M, Al A, Payne K, De Leon M. Hyperglycemia magnifies Schwann cell dysfunction and cell death triggered by PA-induced lipotoxicity. Brain Res. 2011;1370:64–79.CrossRefGoogle Scholar
  6. 6.
    Toth C, Brussee V, Martinez JA, McDonald D, Cunningham FA, Zochodne DW. Rescue and regeneration of injured peripheral nerve axons by intrathecal insulin. Neuroscience. 2006;139(2):429–49.CrossRefGoogle Scholar
  7. 7.
    Kim B, Feldman EL. Insulin resistance in the nervous system. Trends Endocrinol Metab. 2012;23(3):133–41.CrossRefGoogle Scholar
  8. 8.
    Vinik AI. Clinical practice. Diabetic sensory and motor neuropathy. N Engl J Med. 2016;374(15):1455–64.CrossRefGoogle Scholar
  9. 9.
    Waldfogel JM, Nesbit SA, Dy SM, Sharma R, Zhang A, Wilson LM, et al. Pharmacotherapy for diabetic peripheral neuropathy pain and quality of life: a systematic review. Neurology. 2017;88(20):1958–67.CrossRefGoogle Scholar
  10. 10.
    Freeman R, Durso-Decruz E, Emir B. Efficacy, safety, and tolerability of pregabalin treatment for painful diabetic peripheral neuropathy: findings from seven randomized, controlled trials across a range of doses. Diabetes Care. 2008;31(7):1448–54.CrossRefGoogle Scholar
  11. 11.
    Vedula SS, Bero L, Scherer RW, Dickersin K. Outcome reporting in industry-sponsored trials of gabapentin for off-label use. N Engl J Med. 2009;361(20):1963–71.CrossRefGoogle Scholar
  12. 12.
    Saarto T, Wiffen PJ. Antidepressants for neuropathic pain. Cochrane Database Syst Rev. 2007;4:CD005454.Google Scholar
  13. 13.
    Sindrup SH, Otto M, Finnerup NB, Jensen TS. Antidepressants in the treatment of neuropathic pain. Basic Clin Pharmacol Toxicol. 2005;96(6):399–409.CrossRefGoogle Scholar
  14. 14.
    Max MB, Culnane M, Schafer SC, Gracely RH, Walther DJ, Smoller B, et al. Amitriptyline relieves diabetic neuropathy pain in patients with normal or depressed mood. Neurology. 1987;37(4):589–96.CrossRefGoogle Scholar
  15. 15.
    Bril V, England J, Franklin GM, Backonja M, Cohen J, Del Toro D, et al. Evidence-based guideline: treatment of painful diabetic neuropathy: report of the American Academy of Neurology, the American Association of Neuromuscular and Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation. PM R. 2011;3(4):345–52, 52.e1–21.Google Scholar
  16. 16.
    Gallagher HC, Gallagher RM, Butler M, Buggy DJ, Henman MC. Venlafaxine for neuropathic pain in adults. Cochrane Database Syst Rev. 2015;8:CD011091.Google Scholar
  17. 17.
    Gaskell H, Derry S, Stannard C, Moore RA. Oxycodone for neuropathic pain in adults. Cochrane Database Syst Rev. 2016;7:CD010692.Google Scholar
  18. 18.
    Callaghan BC, Cheng HT, Stables CL, Al S, Feldman EL. Diabetic neuropathy: clinical manifestations and current treatments. Lancet Neurol. 2012;11(6):521–34.CrossRefGoogle Scholar
  19. 19.
    Ziegler D, Ametov A, Barinov A, Dyck PJ, Gurieva I, Low PA, et al. Oral treatment with alpha-lipoic acid improves symptomatic diabetic polyneuropathy: the SYDNEY 2 trial. Diabetes Care. 2006;29(11):2365–70.CrossRefGoogle Scholar
  20. 20.
    Attal N, Cruccu G, Baron R, Haanpaa M, Hansson P, Jensen TS, et al. EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision. Eur J Neurol. 2010;17(9):1113–e88.CrossRefGoogle Scholar
  21. 21.
    Dworkin RH, O’Connor AB, Audette J, Baron R, Gourlay GK, Haanpää MI, et al. Recommendations for the pharmacological management of neuropathic pain: an overview and literature update. Mayo Clin Proc. 2010;85(3 Suppl):S3–14.CrossRefGoogle Scholar
  22. 22.
    Effect of intensive diabetes treatment on nerve conduction in the Diabetes Control and Complications Trial. Ann Neurol. 1995;38(6):869–80.Google Scholar
  23. 23.
    Amato S, Sharma R, Waldfogel JM, Zhang A, Bennett WL, Yeh HC, et al. Non-pharmacologic treatments for symptoms of diabetic peripheral neuropathy: a systematic review. Curr Med Res Opin. 2018 Aug;17:1–11.Google Scholar
  24. 24.
    Huygen F, Kallewaard JW, Tulder M, Boxem M, Vissers K, Kleef M, Zundert JV. Evidence-based interventional pain medicine according to clinical diagnoses: update, vol. 19; 2018. p. 664. Scholar
  25. 25.
    Mai L, Clark A, Gordon A, Lynch M, Morley-Forster P, Nathan H, et al. Long-term outcomes in the management of painful diabetic neuropathy. Can J Neurol Sci. 2017;44(4):337–42.CrossRefGoogle Scholar
  26. 26.
    Bharucha NE, Bharucha AE, Bharucha EP. Prevalence of peripheral neuropathy in the Parsi community of Bombay. Neurology. 1991;41(8):1315–7.CrossRefGoogle Scholar
  27. 27.
    Savettieri G, Rocca WA, Salemi G, Meneghini F, Grigoletto F, Morgante L, et al. Prevalence of diabetic neuropathy with somatic symptoms: a door-to-door survey in two Sicilian municipalities. Sicilian Neuro-Epidemiologic Study (SNES) Group. Neurology. 1993;43(6):1115–20.CrossRefGoogle Scholar
  28. 28.
    Maser RE, Steenkiste AR, Dorman JS, Nielsen VK, Bass EB, Manjoo Q, et al. Epidemiological correlates of diabetic neuropathy. Report from Pittsburgh Epidemiology of Diabetes Complications Study. Diabetes. 1989;38(11):1456–61.CrossRefGoogle Scholar
  29. 29.
    Daousi C, MacFarlane IA, Woodward A, Nurmikko TJ, Bundred PE, Benbow SJ. Chronic painful peripheral neuropathy in an urban community: a controlled comparison of people with and without diabetes. Diabet Med. 2004;21(9):976–82.CrossRefGoogle Scholar
  30. 30.
    Davies M, Brophy S, Williams R, Taylor A. The prevalence, severity, and impact of painful diabetic peripheral neuropathy in type 2 diabetes. Diabetes Care. 2006;29(7):1518–22.CrossRefGoogle Scholar
  31. 31.
    Olaleye D, Perkins BA, Bril V. Evaluation of three screening tests and a risk assessment model for diagnosing peripheral neuropathy in the diabetes clinic. Diabetes Res Clin Pract. 2001;54(2):115–28.CrossRefGoogle Scholar
  32. 32.
    Consensus statement: Report and recommendations of the San Antonio conference on diabetic neuropathy. American Diabetes Association American Academy of Neurology. Diabetes Care. 1988;11(7):59207.Google Scholar
  33. 33.
    Dyck PJ, Albers JW, Andersen H, Arezzo JC, Biessels GJ, Bril V, et al. Diabetic polyneuropathies: update on research definition, diagnostic criteria and estimation of severity. Diabetes Metab Res Rev. 2011;27(7):620–8.CrossRefGoogle Scholar
  34. 34.
    Callaghan BC, Little AA, Feldman EL, Hughes RA. Enhanced glucose control for preventing and treating diabetic neuropathy. 2012;6:CD007543.Google Scholar
  35. 35.
    Hamza MA, White PF, Craig WF, Ghoname ES, Ahmed HE, Proctor TJ, et al. Percutaneous electrical nerve stimulation: a novel analgesic therapy for diabetic neuropathic pain. Diabetes Care. 2000;23(3):365–70.CrossRefGoogle Scholar
  36. 36.
    de Vos CC, Meier K, Zaalberg PB, Nijhuis HJ, Duyvendak W, Vesper J, et al. Spinal cord stimulation in patients with painful diabetic neuropathy: a multicentre randomized clinical trial. Pain. 2014;155(11):2426–31.CrossRefGoogle Scholar
  37. 37.
    van Beek M, Slangen R, Schaper NC, Faber CG, Joosten EA, Dirksen CD, et al. Sustained treatment effect of spinal cord stimulation in painful diabetic peripheral neuropathy: 24-month follow-up of a prospective two-center randomized controlled trial. Diabetes Care. 2015;38(9):e132–4.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  1. 1.Department of NeurologyUniversity of Vermont Medical CenterBurlingtonUSA
  2. 2.Department of NeurosciencesUniversity of Vermont Medical CenterBurlingtonUSA

Personalised recommendations